Evidence mapPaperPMID 39694849Full record

Observational studyJournal of medical Internet research2025

Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study.

Chenxi Li, Lixin Guo, Lixin Shi, Li Chen, Liming Chen, Yaoming Xue, Hong Li, Yuzhen Liang, Jing Yang, Weimin Wang and 1 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chenxi LiDepartment of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing Medical School, Nanjing, China.ORCID https://orcid.org/0000-0001-7489-7234
Lixin GuoDepartment of Endocrinology, Peking Union Medical College, Chinese Academy of Nanjing Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0003-2596-8387
Lixin ShiDepartment of Endocrinology, Affiliated Hospital of Guiyang Medical University, Guiyang, China.ORCID https://orcid.org/0000-0002-0389-2732
Li ChenDepartment of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.ORCID https://orcid.org/0000-0001-7670-8062
Liming ChenNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.ORCID https://orcid.org/0000-0001-6171-3432
Yaoming XueDepartment of Endocrinology & Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-3570-1099
Hong LiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-0284-2282
Yuzhen LiangDepartment of Endocrinology, The Second Affiliated Hospital of Guangxi Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-1958-5024
Jing YangDepartment of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.ORCID https://orcid.org/0000-0001-8855-6254
Weimin Wang *Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing Medical School, Nanjing, China.ORCID https://orcid.org/0000-0002-8843-131X
Dalong Zhu *Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing Medical School, Nanjing, China.ORCID https://orcid.org/0000-0002-1064-1261

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes, a chronic disease necessitating long-term treatment and self-management, presents significant challenges for patients who spend most of their treatment time outside of hospitals. The potential of digital therapeutics for diabetes has garnered recognition from different organizations. Although some prior studies have demonstrated successful reductions in patients' blood glucose levels and body weight through digital diabetes programs, many studies were limited by including patients with prediabetes, including patients treated with mostly premixed insulin, or evaluating user engagement outcomes rather than clinical outcomes. Consequently, limited evidence remains regarding the effectiveness of health management mobile apps specifically designed for patients with type 2 diabetes mellitus (T2DM) initiating basal insulin (BI). Based on this, a data-based and artificial intelligence management system named "TRIO" was developed to provide patients with more personalized intervention methods in stages, in groups, and around the clock. TRIO assists doctors and nurses in achieving better blood glucose controls, truly carries out standardized management around patients, and allows them to have a higher quality of life. TRIO represents the 3 essential pillars in comprehensive diabetes management: physician, nurse, and patient.

objectiveThis prospective observational study evaluated the effectiveness and safety of the TRIO optimal health management program for patients with T2DM initiating BI therapy in a real-world setting.

methodsPatients aged 18-85 years with inadequate glycemic control (baseline hemoglobin A

resultsA total of 199,431 patients were included, and 118,134 patients completed the 3-month follow-up between December 1, 2019, and December 31, 2021, involving 574 hospitals in China. The mean baseline HbA

conclusionsThe TRIO optimal health management program effectively improved glycemic control in patients with T2DM initiating BI therapy. Individualized treatment approaches considering patient characteristics and glycemic goals are vital for optimal outcomes.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinAdultAgedBlood GlucoseFemaleGlycated HemoglobinHumansMaleMiddle AgedMobile ApplicationsProspective StudiesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinglycemic controlinitiating basal insulin therapyreal-world studyTRIO optimal health management programtype 2 diabetes

Identifiers

PMID39694849
PMCPMC11773279

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.